Evidence map›Paper›PMID 40852923›Full record

ArticleCNS neuroscience & therapeutics2025

Cannabinoid Receptors CB1 and CB2 Activation Restores Hippocampal Lipid Profiles and Alleviates Autism-Like Behaviors in Valproic Acid-Induced ASD Rats.

Haoran Wang, Mengyuan Zhang, Sen Yang, Yi Jiang, Lijie Wu, Caihong Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Haoran WangDepartment of Children's and Adolescent Health, Public Health College, Harbin Medical University, Harbin, China.
Mengyuan ZhangDepartment of Children's and Adolescent Health, Public Health College, Harbin Medical University, Harbin, China.
Sen YangDepartment of Children's and Adolescent Health, Public Health College, Harbin Medical University, Harbin, China.
Yi JiangDepartment of Children's and Adolescent Health, Public Health College, Harbin Medical University, Harbin, China.
Lijie WuDepartment of Children's and Adolescent Health, Public Health College, Harbin Medical University, Harbin, China.ORCID 0000-0002-0631-5076
Caihong SunDepartment of Children's and Adolescent Health, Public Health College, Harbin Medical University, Harbin, China.ORCID 0000-0002-1798-0768

Funding

National Natural Science Foundation of China 82173535Natural Science Foundation of Heilongjiang Province No.LH2023H017
6 · The paper itself

Abstract

objectiveEmerging evidence suggests lipid metabolism dysregulation contributes to autism spectrum disorders (ASD), with the endocannabinoid system (cannabinoid receptors CB1R/CB2R) implicated in lipid homeostasis. This study investigated whether CB1R/CB2R activation improves hippocampal lipid metabolism and ASD-like behaviors in a valproic acid (VPA)-induced ASD rat model.

methodsMale offspring from dams exposed to VPA (600 mg/kg, i.p.) received the CB1R agonist ACPA (0.1 mg/kg) or the CB2R agonist AM1241 (3 mg/kg) from postnatal days 21-27. ASD-like behaviors (marble burying, self-grooming, social interaction, open-field tests) and hippocampal lipid profiles (UPLC-MS/MS) were analyzed.

resultsVPA-exposed rats displayed heightened repetitive behaviors, social deficits, and hyperactivity, all significantly alleviated by ACPA and AM1241. Lipidomics revealed marked reductions in hippocampal phosphatidylcholines, lysophosphatidylcholines, fatty acids, sphingomyelins, ceramides, and phosphatidylethanolamines in VPA rats. Both agonists restored lipid levels to near normal, comparable to controls.

conclusionsCB1R/CB2R activation ameliorates behavioral abnormalities and rectifies hippocampal lipid dysregulation in VPA-induced ASD models, highlighting cannabinoid receptors as potential therapeutic targets for ASD-associated metabolic disturbances.

Indexed as

Autism Spectrum DisorderHippocampusLipid MetabolismReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Valproic AcidAnimalsBehavior, AnimalCannabinoid Receptor AgonistsFemaleMalePregnancyRatsRats, Sprague-DawleyCannabinoid Receptor AgonistsCnr2 protein, ratReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Valproic Acidautism spectrum disorderscannabinoid receptor 1cannabinoid receptor 2lipidomics

Identifiers

PMID40852923
PMCPMC12376063

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.